[go: up one dir, main page]

MX2022000358A - Preparacion farmaceutica. - Google Patents

Preparacion farmaceutica.

Info

Publication number
MX2022000358A
MX2022000358A MX2022000358A MX2022000358A MX2022000358A MX 2022000358 A MX2022000358 A MX 2022000358A MX 2022000358 A MX2022000358 A MX 2022000358A MX 2022000358 A MX2022000358 A MX 2022000358A MX 2022000358 A MX2022000358 A MX 2022000358A
Authority
MX
Mexico
Prior art keywords
pharmaceutical preparation
ylmethoxy
pyridazin
benzonitrile
pyrimidin
Prior art date
Application number
MX2022000358A
Other languages
English (en)
Inventor
Markus Weigandt
Corinna Schoch
Markus Riehl
Gero Hooff
Markus Klemm
Carsten Schmidt
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67226151&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022000358(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2022000358A publication Critical patent/MX2022000358A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a una preparación farmacéutica sólida de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il ]-bencil}-6-oxo-1,6-dihidro-piridazin-3-il)-benzonitrilo, un método para hacer la misma y usos médicos de la misma.
MX2022000358A 2019-07-10 2020-07-08 Preparacion farmaceutica. MX2022000358A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19185500 2019-07-10
PCT/EP2020/069165 WO2021005077A1 (en) 2019-07-10 2020-07-08 Pharmaceutical preparation

Publications (1)

Publication Number Publication Date
MX2022000358A true MX2022000358A (es) 2022-02-03

Family

ID=67226151

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000358A MX2022000358A (es) 2019-07-10 2020-07-08 Preparacion farmaceutica.

Country Status (21)

Country Link
US (1) US20220288068A1 (es)
EP (2) EP4260910A3 (es)
JP (1) JP7682847B2 (es)
KR (1) KR20220034183A (es)
CN (3) CN118986988A (es)
AU (1) AU2020309149A1 (es)
BR (1) BR112022000266A2 (es)
CA (1) CA3146384A1 (es)
DK (1) DK3996688T3 (es)
ES (1) ES2966788T3 (es)
FI (1) FI3996688T3 (es)
HR (1) HRP20231548T1 (es)
HU (1) HUE064434T2 (es)
IL (1) IL289481A (es)
LT (1) LT3996688T (es)
MX (1) MX2022000358A (es)
PL (1) PL3996688T3 (es)
PT (1) PT3996688T (es)
RS (1) RS64906B1 (es)
SI (1) SI3996688T1 (es)
WO (1) WO2021005077A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115919866A (zh) * 2022-12-07 2023-04-07 深圳海王医药科技研究院有限公司 特泊替尼固体分散体及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6600069B2 (en) * 2000-09-07 2003-07-29 Telik, Inc. Benzene tricarboxylic acid derivatives as insulin receptor activators
US8545881B2 (en) * 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
SG10201504735QA (en) * 2009-01-08 2015-07-30 Merck Patent Gmbh Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
EP2827872A1 (en) * 2012-03-19 2015-01-28 Merck Patent GmbH Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds
LT2914264T (lt) * 2012-11-02 2017-11-10 Merck Patent Gmbh 6-okso-1,6-dihidro-piridazino darinys, skirtas naudoti hepatoceliulinės karcinomos (hcc) gydymui
US20160331748A1 (en) * 2014-01-07 2016-11-17 Merck Patent Gmbh A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (RCC)
CA2970394C (en) * 2014-12-11 2023-03-14 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative

Also Published As

Publication number Publication date
HRP20231548T1 (hr) 2024-03-15
FI3996688T3 (fi) 2023-11-30
US20220288068A1 (en) 2022-09-15
CN118986987A (zh) 2024-11-22
EP3996688A1 (en) 2022-05-18
CA3146384A1 (en) 2021-01-14
HUE064434T2 (hu) 2024-03-28
EP3996688B1 (en) 2023-09-06
AU2020309149A1 (en) 2022-03-03
EP4260910A3 (en) 2023-12-27
BR112022000266A2 (pt) 2022-05-17
ES2966788T3 (es) 2024-04-24
LT3996688T (lt) 2023-12-27
CN118986988A (zh) 2024-11-22
IL289481A (en) 2022-02-01
KR20220034183A (ko) 2022-03-17
CN114025761B (zh) 2024-07-16
SI3996688T1 (sl) 2024-01-31
EP4260910A2 (en) 2023-10-18
RS64906B1 (sr) 2023-12-29
PL3996688T3 (pl) 2024-02-12
DK3996688T3 (da) 2023-11-27
PT3996688T (pt) 2023-11-29
WO2021005077A1 (en) 2021-01-14
JP7682847B2 (ja) 2025-05-26
CN114025761A (zh) 2022-02-08
JP2022540170A (ja) 2022-09-14

Similar Documents

Publication Publication Date Title
CR20130649A (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
BRPI0922642A2 (pt) "formas polimórficas de sal de cloridrato de 3-(1-{3[5-(1-metil-piperidin-4-ilmetóxi)-piridin-2-il]-benzil}-6-oxo-1,6-di-hidro-piridazin-3-il)-benzonitrila e processos de fabricação do mesmo"
CY1121421T1 (el) Φαρμακοτεχνικες μορφες
CL2018000436A1 (es) Alcoholes trifluorometílicos como moduladores de roryt (divisional solicitud 201701042).
HK1244429A1 (zh) 特別用於治療注意力缺陷障礙的方法和組合物
BR112016017010A2 (pt) Anticorpo monoclonal de fator antitecido
MX388586B (es) Combinacion farmaceutica que comprende un bloqueador del canal de calcio de tipo t.
DOP2018000103A (es) Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona para tratar enfermedad de parkinson.
MX2022000498A (es) Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihi dro-1h-inden-1-il) -2-metil-2h- tetrazol-5-carboxamida.
MX2022000358A (es) Preparacion farmaceutica.
MX2020014159A (es) Estructuras porosas cargables para usarse como implantes.
CL2017001477A1 (es) Combinación de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cáncer con un derivado de quinazolina
BR112015010121A2 (pt) inibidores de quinase de tirosina de bruton
PH12017500718A1 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor
BR112017017783A2 (pt) Ácido (2r,4r)-5-(5'-cloro-2'-fluorbifenil-4-il)-2-hidróxi- 4-[(5-metiloxazol-2-carbonil)amino]pentanóico.
AR092991A1 (es) Combinacion de un derivado de a 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancer con un inhibidor de proteinquinasa activada por mitogenos (mek)
PH12016500948A1 (en) Combination of a 6-oxo- 1,6-dihydro-pyridazine derivate having anti-cancer activity with gefitinib
DK3408260T3 (da) Krystallinsk (2s,4r)-5-(5'-chlor-2-fluor-[1,1'-biphenyl]-4-yl)-2-(ethoxy¬methyl)-4-(3-hydroxyisoxazol-5-carboxamido)-2-methylpentansyre og anvendelser deraf
CU20190066A7 (es) Compuestos derivados de 6-cloro-n-(4,4-difluorociclohexil)-2-(3-metil-1h-pirazol-1-il)pirimidin-4-amina y 6-cloro-n-(4,4-difluorociclohexil)-2-(4-metiltiazol-2-il)pirimidin-4-amina como moduladores del canal de potasio
BR112017012547A2 (pt) Composições de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h- indazol-5-il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il) fenil)-3,6-diidropiridin-1(2h)-il)-2-oxoetil)-3-(metiltio) pirrolidina-3-carboxamida para preparações farmacêuticas
MX2020003431A (es) Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol- 2,5-diona.
CA2890273C (en) A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc)
DK3585776T3 (da) 5-(pyrimidin-4-yl)-2-(pyrrolidin-1-yl)nicotinonitril-forbindelser som ikke, tbk1 og/eller sik2 kinaseinhibitorer
PH12016500964A1 (en) A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (rcc)
EP3603643A4 (en) MEDICINAL COMPOSITION IN TABLETS CONTAINING NALFURAFINE